EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy

Rossana Roncato, Diletta Pasin, Emanuela Dell Apos Aquila, Romano Danesi, Marzia Del Re

Chemotherapy · 29.06.2026 · 1-24

DOI: 10.1159/000553142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemotherapy, online erschienen am 29.06.2026. Verfasst von Rossana Roncato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Udine, Udine, Italy. Die Arbeit nennt 174 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Monoclonal antibodies (mAbs) and their derivatives represent a central pillar of contemporary oncology, with expanding complexity in molecular design and clinical application. Beyond unconjugated mAbs, bispecific antibodies (bsAbs), trispecific antibodies (tsAbs), and antibody-drug conjugates (ADCs) introduce additional pharmacological dimensions that directly impact efficacy, toxicity, and resistance. BsAbs were developed as pharmacological matchmakers to simultaneously engage tumor antigens and immune receptors, physically bridging effectors and malignant cells to promote immunological synapse formation. TsAbs extend this concept by enabling coordinated engagement of three targets. ADCs exploit mAb specificity to deliver highly potent, otherwise intolerable cytotoxic payloads directly into tumor cells, expanding the therapeutic window in hematologic and solid tumors. Summary: Clinical performance is tightly linked to molecular architecture: bsAb/tsAb activity depends on valency, target geometry, and Fc configuration, whereas ADC efficacy reflects a tripartite pharmacology integrating target engagement, intracellular payload release, and bystander cytotoxicity. Despite their remarkable potency, antibody-based platforms remain vulnerable to resistance, which may arise through target-dependent mechanisms, including antigen downregulation and epitope masking, or target-independent processes, such as altered intracellular trafficking, lysosomal dysfunction, payload efflux, and adaptive survival signaling. Key Message: A comprehensive understanding of antibody architecture, target biology, pharmacokinetic/pharmacodynamic behavior, toxicity profiles, and resistance mechanisms is essential to optimize treatment selection and sequencing. Collectively, mAbs, bsAbs/tsAbs, and ADCs provide the mechanistic and technological basis for next-generation platforms, including peptide-drug conjugates and antibody-radionuclide conjugates.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugateBispecific/trispecific antibodiesCancer immunotherapyPharmacokineticsResistance mechanismsTargeted therapy

Autor:innen und Institutionen

  • Department of Medicine, University of Udine, Udine, Italy.
  • Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • IRCCS Regina Elena National Cancer Institute, Rome, Italy, emanuela.dellaquila@ifo.it.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
  • IRCCS Istituto Dermopatico dell'Immacolata, Rome, Italy.

Zitieren

APA

Roncato, R., Pasin, D., Dell Apos Aquila, E., Danesi, R., & Del Re, M. (2026). Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy. Chemotherapy, 1-24. https://doi.org/10.1159/000553142

Vancouver

Roncato R, Pasin D, Dell Apos Aquila E, Danesi R, Del Re M. Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy. Chemotherapy. 2026:1-24. doi:10.1159/000553142

BibTeX
@article{Roncato2026,
  author = {Roncato, Rossana and Pasin, Diletta and Dell Apos Aquila, Emanuela and Danesi, Romano and Del Re, Marzia},
  title = {Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy},
  journal = {Chemotherapy},
  year = {2026},
  pages = {1--24},
  doi = {10.1159/000553142}
}
Kostenlos starten →